210 related articles for article (PubMed ID: 35932086)
1. Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study.
Kang YR; Kim SH; Chung DR; Ko JH; Huh K; Cho SY; Kang CI; Peck KR
Antimicrob Resist Infect Control; 2022 Aug; 11(1):101. PubMed ID: 35932086
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
[TBL] [Abstract][Full Text] [Related]
4. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
5. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
6. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.
Hu J; Ma XX; Tian Y; Pang L; Cui LZ; Shang H
PLoS One; 2013; 8(9):e73300. PubMed ID: 24069184
[TBL] [Abstract][Full Text] [Related]
7. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
Ozmen Capin BB; Tekeli A; Karahan ZC
Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
[No Abstract] [Full Text] [Related]
9. Prevalence and molecular characteristics of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern China.
Cheng X; Ma L; Wang Y; Sun W; Su J
Diagn Microbiol Infect Dis; 2024 Mar; 108(3):116180. PubMed ID: 38183897
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study.
Yamakawa J; Aminaka M; Okuzumi K; Kobayashi H; Katayama Y; Kondo S; Nakamura A; Oguri T; Hori S; Cui L; Ito T; Jin J; Kurosawa H; Kaneko K; Hiramatsu K
J Infect Chemother; 2012 Jun; 18(3):406-9. PubMed ID: 22033576
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.
Zhang S; Sun X; Chang W; Dai Y; Ma X
PLoS One; 2015; 10(8):e0136082. PubMed ID: 26287490
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.
Matsuo M; Cui L; Kim J; Hiramatsu K
Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261
[TBL] [Abstract][Full Text] [Related]
14. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
Howden BP; Smith DJ; Mansell A; Johnson PD; Ward PB; Stinear TP; Davies JK
BMC Microbiol; 2008 Feb; 8():39. PubMed ID: 18304359
[TBL] [Abstract][Full Text] [Related]
15. Impact of mutations in hVISA isolates on decreased susceptibility to vancomycin, through population analyses profile - area under curve (PAP-AUC).
Silveira ACO; Caierão J; Silva CI; Anzai EK; McCulloch JA; d'Azevedo PA; Sincero TCM
Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114854. PubMed ID: 31366440
[TBL] [Abstract][Full Text] [Related]
16. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
Çıkman A; Aydın M; Gülhan B; Parlak M; Gültepe B; Kalaycı Y; Bayındır Bilmen F; Solmaz S; Özekinci T
Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Clinical Features of Heterogeneous Vancomycin-Intermediate
Sreejisha M; Shenoy MS; Shenoy MS; Dhanashree B; Chakrapani M; Bhat KG
Sultan Qaboos Univ Med J; 2023 Nov; 23(4):447-454. PubMed ID: 38090245
[TBL] [Abstract][Full Text] [Related]
18. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.
Howden BP; Peleg AY; Stinear TP
Infect Genet Evol; 2014 Jan; 21():575-82. PubMed ID: 23567819
[TBL] [Abstract][Full Text] [Related]
19. Etest Methods for Screening Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) strains.
Lee MY; Lee WI; Kim MH; Kang SY; Kim YJ
Curr Microbiol; 2020 Oct; 77(10):3158-3167. PubMed ID: 32734419
[TBL] [Abstract][Full Text] [Related]
20. Development of an Amplicon Nanopore Sequencing Strategy for Detection of Mutations Conferring Intermediate Resistance to Vancomycin in Staphylococcus aureus Strains.
Moller AG; Petit RA; Davis MH; Read TD
Microbiol Spectr; 2023 Feb; 11(1):e0272822. PubMed ID: 36688645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
